Cardiff Oncology Inc expected to post a loss of 26 cents a share - Earnings Preview

Cardiff Oncology

31/10/2022 11:45

* Cardiff Oncology Inc  CRDF.OQ   CRDF.O  is expected
to show a
fall in quarterly revenue when it reports  results on November 2
(estimated). 
    * The San Diego California-based  company is expected to
report  a
20.7% decrease in revenue to $68.2 thousand from $86 thousand a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Cardiff Oncology
Inc is
for a loss of 26 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is $5​, above​ its last closing price of $1.56. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.26       -0.25      -0.24     Beat    4.8
 Mar. 31 2022  -0.25       -0.23      -0.25     Missed  -8.2
 Dec. 31 2021  -0.17       -0.17      -0.23     Missed  -34​
 Sep. 30 2021  -0.17       -0.17      -0.17     Met     0
 ​​Jun.        -0.15       -0.15      -0.17     Missed  -13.5
 30 2021                                                
 Mar. 31 2021  -0.16       -0.15      -0.14     Beat    5.1​
 Dec. 31 2020  -0.15       -0.14      -0.19     Missed  -35.7
 Sep. 30 2020  -0.19       -0.19      -0.19     Met     -1.8
 This summary was machine generated October 31 at 11:45 GMT.  All
figures in US dollars  unless otherwise stated